NanoVibronix completes UroShield pilot study; Nasdaq panel grants limited extension with conditions

ENvue Medical, Inc.

Completed pilot phase of UroShield RCT at Univ. of Michigan; full trial to begin in 2025.
Pilot focused on nursing home residents, studying reduction of UTIs, catheter blockages and pain.
Nasdaq panel granted extension until March 31, 2025 to meet bid price and equity rules.
Conditions: stockholder approval for reverse split by Feb 27, 2025; effect split and show $1.00 bid for 10 consecutive days.
Must also demonstrate compliance with $2.5M stockholders' equity requirement; delisting risk remains.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.